We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase I study evaluates CSL889's safety and pharmacokinetics in adults with sickle cell anemia, suggesting potential therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Biemond et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: